104 related articles for article (PubMed ID: 20729728)
1. Late-onset gain of skills and peculiar jugular pit in an 11-year-old girl with 5q14.3 microdeletion including MEF2C.
Berland S; Houge G
Clin Dysmorphol; 2010 Oct; 19(4):222-224. PubMed ID: 20729728
[No Abstract] [Full Text] [Related]
2. The MEF2C gene-microdeletion 5q14.3 dilemma and three axioms for molecular syndromology.
Wilson GN
Am J Med Genet A; 2013 Apr; 161A(4):916-7. PubMed ID: 23495102
[No Abstract] [Full Text] [Related]
3. De novo microdeletion of 5q14.3 excluding MEF2C in a patient with infantile spasms, microcephaly, and agenesis of the corpus callosum.
Shimojima K; Okumura A; Mori H; Abe S; Ikeno M; Shimizu T; Yamamoto T
Am J Med Genet A; 2012 Sep; 158A(9):2272-6. PubMed ID: 22848023
[TBL] [Abstract][Full Text] [Related]
4. Jugular pit associated with 5q14.3 deletion incorporating the MEF2C locus: a recurrent clinical finding.
Al-Shehhi M; Betts D; Mc Ardle L; Donoghue V; Reardon W
Clin Dysmorphol; 2016 Jan; 25(1):23-6. PubMed ID: 26426104
[No Abstract] [Full Text] [Related]
5. An intellectually disabled patient with the 5q14.3q15 microdeletion syndrome associated with an apparently de novo t(2;5)(q13;q14).
Toral-López J; Buentello-Volante B; Balderas-Minor MM; Amezcua-Herrera C; Valdes-Miranda JM; González-Huerta LM; Gudiño M; Cuevas-Covarrubias SA; Zenteno JC
Am J Med Genet A; 2012 Apr; 158A(4):942-6. PubMed ID: 22419405
[No Abstract] [Full Text] [Related]
6. 5q14.3 neurocutaneous syndrome: a novel continguous gene syndrome caused by simultaneous deletion of RASA1 and MEF2C.
Carr CW; Zimmerman HH; Martin CL; Vikkula M; Byrd AC; Abdul-Rahman OA
Am J Med Genet A; 2011 Jul; 155A(7):1640-5. PubMed ID: 21626678
[TBL] [Abstract][Full Text] [Related]
7. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations.
Le Meur N; Holder-Espinasse M; Jaillard S; Goldenberg A; Joriot S; Amati-Bonneau P; Guichet A; Barth M; Charollais A; Journel H; Auvin S; Boucher C; Kerckaert JP; David V; Manouvrier-Hanu S; Saugier-Veber P; Frébourg T; Dubourg C; Andrieux J; Bonneau D
J Med Genet; 2010 Jan; 47(1):22-9. PubMed ID: 19592390
[TBL] [Abstract][Full Text] [Related]
8. De novo 5q14.3 translocation 121.5-kb upstream of MEF2C in a patient with severe intellectual disability and early-onset epileptic encephalopathy.
Saitsu H; Igarashi N; Kato M; Okada I; Kosho T; Shimokawa O; Sasaki Y; Nishiyama K; Tsurusaki Y; Doi H; Miyake N; Harada N; Hayasaka K; Matasumoto N
Am J Med Genet A; 2011 Nov; 155A(11):2879-84. PubMed ID: 21990267
[TBL] [Abstract][Full Text] [Related]
9. Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.
Zweier M; Gregor A; Zweier C; Engels H; Sticht H; Wohlleber E; Bijlsma EK; Holder SE; Zenker M; Rossier E; Grasshoff U; Johnson DS; Robertson L; Firth HV; ; Ekici AB; Reis A; Rauch A
Hum Mutat; 2010 Jun; 31(6):722-33. PubMed ID: 20513142
[TBL] [Abstract][Full Text] [Related]
10. Interstitial deletion 5q14.3q21.3 with MEF2C haploinsufficiency and mild phenotype: when more is less.
Tonk V; Kyhm JH; Gibson CE; Wilson GN
Am J Med Genet A; 2011 Jun; 155A(6):1437-41. PubMed ID: 21567930
[TBL] [Abstract][Full Text] [Related]
11. Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C.
Nowakowska BA; Obersztyn E; Szymańska K; Bekiesińska-Figatowska M; Xia Z; Ricks CB; Bocian E; Stockton DW; Szczałuba K; Nawara M; Patel A; Scott DA; Cheung SW; Bohan TP; Stankiewicz P
Am J Med Genet B Neuropsychiatr Genet; 2010 Jul; 153B(5):1042-51. PubMed ID: 20333642
[TBL] [Abstract][Full Text] [Related]
12. Refining the phenotype associated with MEF2C point mutations.
Bienvenu T; Diebold B; Chelly J; Isidor B
Neurogenetics; 2013 Feb; 14(1):71-5. PubMed ID: 23001426
[TBL] [Abstract][Full Text] [Related]
13. Prenatal detection of 5q14.3 duplication including MEF2C and brain phenotype.
Cesaretti C; Spaccini L; Righini A; Parazzini C; Conte G; Crosti F; Redaelli S; Bulfamante G; Avagliano L; Rustico M
Am J Med Genet A; 2016 May; 170A(5):1352-7. PubMed ID: 26864752
[TBL] [Abstract][Full Text] [Related]
14. Microdeletion 5q14.3 and anomalies of brain development.
Hotz A; Hellenbroich Y; Sperner J; Linder-Lucht M; Tacke U; Walter C; Caliebe A; Nagel I; Saunders DE; Wolff G; Martin P; Morris-Rosendahl DJ
Am J Med Genet A; 2013 Sep; 161A(9):2124-33. PubMed ID: 23824879
[TBL] [Abstract][Full Text] [Related]
15. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines.
Nagel S; Meyer C; Quentmeier H; Kaufmann M; Drexler HG; MacLeod RA
Leukemia; 2008 Mar; 22(3):600-7. PubMed ID: 18079734
[TBL] [Abstract][Full Text] [Related]
16. Regional chromosomal assignments for four members of the MADS domain transcription enhancer factor 2 (MEF2) gene family to human chromosomes 15q26, 19p12, 5q14, and 1q12-q23.
Hobson GM; Krahe R; Garcia E; Siciliano MJ; Funanage VL
Genomics; 1995 Oct; 29(3):704-11. PubMed ID: 8575763
[TBL] [Abstract][Full Text] [Related]
17. Refining the phenotype associated with MEF2C haploinsufficiency.
Novara F; Beri S; Giorda R; Ortibus E; Nageshappa S; Darra F; Dalla Bernardina B; Zuffardi O; Van Esch H
Clin Genet; 2010 Nov; 78(5):471-7. PubMed ID: 20412115
[TBL] [Abstract][Full Text] [Related]
18. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.
Homminga I; Pieters R; Langerak AW; de Rooi JJ; Stubbs A; Verstegen M; Vuerhard M; Buijs-Gladdines J; Kooi C; Klous P; van Vlierberghe P; Ferrando AA; Cayuela JM; Verhaaf B; Beverloo HB; Horstmann M; de Haas V; Wiekmeijer AS; Pike-Overzet K; Staal FJ; de Laat W; Soulier J; Sigaux F; Meijerink JP
Cancer Cell; 2011 Apr; 19(4):484-97. PubMed ID: 21481790
[TBL] [Abstract][Full Text] [Related]
19. Hunting osteoporosis susceptibility genes: bigger is better but diverse is also welcome.
Rivadeneira F
Endocrine; 2013 Feb; 43(1):6-7. PubMed ID: 23001603
[No Abstract] [Full Text] [Related]
20. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
